Utility of Genomic Profiling Use for Targeted Therapy in a Phase I Setting Reveals that ESCAT I/II Actionable Targets are Associated with Improved Outcomes By Ogkologos - May 6, 2025 727 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CoPPO study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Cabozantinib and Nivolumab March 4, 2021 Mesothelioma Awareness Day: Spotlight on the PrE0506/DREAM3R Clinical Trial September 23, 2021 Hable con su médico sobre las opciones de cirugía de mama February 13, 2024 FDA Approves Device for Treatment of Osteoid Osteoma in the Extremities December 1, 2020 Load more HOT NEWS EMA Recommends Granting a Marketing Authorisation for Plerixafor Accord EMA Recommends Granting a Marketing Authorisation for Asciminib The rise of the ‘long-waiter’ – why cancer waiting times are... Breast Cancer Patient Fights To Have Mastectomy During COVID-19 Restrictions And...
